Compare Incyte Corporation (INCY) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Incyte Corporation trades at $118.02 (market cap $23.11B), while Global X NASDAQ 100 Covered Call ETF trades at $17.78. The key difference: Incyte Corporation is trading nearer its 52-week high, Global X NASDAQ 100 Covered Call ETF nearer its low. Which is the better fit depends on your goals.
| INCY | QYLD | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $118.52 | $18.52 |
52-Week Low | $67.38 | $16.46 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
QYLD trades at $17.66, down 0.84% with a bearish technical signal from moving averages. The ETF's covered-call strategy generates high income but has underperformed the Nasdaq-100's growth over the long term. Recent dividend payments of $0.18-$0.19 per share continue the fund's income-focused approach while technical indicators show neutral oscillators but bearish momentum signals.
The outlook remains challenging as QYLD's high yield comes at the cost of capital appreciation. While attractive for income-seeking investors, the fund faces structural headwinds in strong bull markets. Key risks include NAV erosion during market rallies and competition from lower-fee alternatives like GPIQ.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
